Objective: The respiratory effects of nebivolol, a new
selective β1-adrenergic blocking agent, and celiprolol, aβ
-blocker possessing strong β1-adrenoceptor antagonist
and mild β2-agonist properties, were investigated in 12
patients with mild asthma.
Design: Changes in several
spirometric indexes (FVC, FEV1, and forced expiratory flow
rate at 50% of FVC) were measured. The interaction with the
bronchodilator effect of the β2-adrenoceptor-selective
agonist albuterol also was investigated.
effect of both nebivolol and celiprolol on FEV1 was
considered to be significant (p < 0.05). The administration of
nebivolol and celiprolol, but not of placebo, elicited a decrease in
FEV1: mean maximum difference for nebivolol, −0.272 L
(95% confidence interval [CI], −0.402 to −0.142); mean maximum
difference for celiprolol, −0.193 L (95% CI, −0.316 to −0.071);
mean maximum difference for placebo, −0.0001 L (95% CI, −0.087 to
0.085). The inhalation of albuterol, up to a dose of 800 μg,
significantly (p < 0.05) improved FEV1, but the values
after nebivolol and celiprolol administration were lower than the
initial values. Both β-blockers caused equal changes in heart rate,
systolic BP, and diastolic BP.
Conclusions: There were
no significant differences between the respiratory actions of the two